bims-amyloi Biomed News
on Amyloid
Issue of 2026–11–08
nine papers selected by
Alexander Röntgen, University of Cambridge



  1. Protein Sci. 2026 Dec;pii: e70849. [Epub ahead of print]35(12):
      Aggregation of the amyloid-β (Aβ) peptide into amyloid oligomers and fibrils is a central pathogenic feature and therapeutic target in Alzheimer's disease (AD). Understanding the aggregation reaction and how it is modulated by the biological environment is therefore important. Cell-secreted extracellular vesicles (EVs) are emerging as modulators of Aβ aggregation, transport and toxicity. Here, we show that EVs from a variety of human and non-human cells have highly similar retarding effects on the rate of Aβ(1-42) fibril formation, suggesting that aggregation inhibition is a common EV feature. Furthermore, we examine how different EV biomolecular classes contribute to shape this effect. We show that enzymatic removal of surface-associated EV proteins significantly enhances their ability to inhibit aggregation. Similar, albeit considerably smaller, alterations were observed upon removal of cell surface protein-associated glycans. This suggests that EV-mediated inhibition of Aβ(1-42) aggregation may primarily be regulated by lipids and that surface proteins function to modulate this effect, through steric hindrance and/or direct interactions with Aβ(1-42) species. We further observed a minor but statistically robust enhancement of EV-mediated Aβ(1-42) aggregation inhibition upon removal of proteoglycans, suggesting that carbohydrates on the EV-surface also contribute to modulate their inhibitory effect. Altogether, these observations contribute mechanistic insight into the role of EVs as modulators of Aβ aggregation and highlight their possible contributions to maintenance of extracellular protein homeostasis.
    Keywords:  Alzheimer's disease; EVs; amyloid kinetics; amyloid‐β; extracellular vesicles; protein aggregation
    DOI:  https://doi.org/10.1002/pro.70849
  2. Res Sq. 2026 Oct 28. pii: rs.3.rs-11285328. [Epub ahead of print]
      Tau amyloid fibrils adopt disease-specific structures across tauopathies, yet the sequence determinants that favor one pathological fold over another remain poorly defined. Here we combine computational saturation mutagenesis and energetic profiling, in vitro aggregation, cryo-EM and cellular seeding assays to identify sequence changes that alter tau fold compatibility. Across six tauopathy fibril structures, approximately 12,000 substitutions revealed that mutational sensitivity is concentrated within interaction networks formed by amyloidogenic motifs rather than uniformly distributed across the fibril core. Comparison of Alzheimer's disease (AD) and chronic traumatic encephalopathy (CTE) folds identified residues within the 335-363 region that differentially influence fold compatibility. The S341L/S352I double mutant accelerated aggregation and remodeled packing within the PAM4-containing amyloidogenic region, producing an alternative amyloid architecture in a minimal tau fragment. S341L/S352I biosensors preferentially responded to CTE-derived over Alzheimer's disease-derived seeds, while aggregates generated from recombinant S341L/S352I tau exhibited CTE-like cellular templating behavior. Although these assemblies are not established to reproduce the atomic CTE fold, the results demonstrate that targeted sequence changes can bias tau aggregation and propagation toward a CTE-compatible state. This framework provides a strategy for defining sequence-structure relationships in polymorphic amyloids and developing conformation-selective models and biosensors.
    DOI:  https://doi.org/10.21203/rs.3.rs-11285328/v1
  3. Protein Sci. 2026 Dec;pii: e70867. [Epub ahead of print]35(12):
      Progressive β cell death resulting from the aggregation of human islet amyloid polypeptide (hIAPP) in the pancreas is a molecular driver of type 2 diabetes (T2D). Recent studies from our group have shown that hIAPP forms two distinct amyloid oligomers: on-path donut oligomers (DOs) and off-path round oligomers (ROs). Previous studies have also shown lipids, one of the most abundant classes of biomolecules within cells, alter the kinetics of hIAPP amyloid formation and template structurally distinct hIAPP fibrils. However, the influence of the specific lipid environment on the evolution of early-stage hIAPP amyloids remains unknown. In this study, we employ atomic force microscopy (AFM) and atomic force microscopy Infrared (AFM-IR) spectroscopy to resolve the morphological and structural dynamics of early-stage hIAPP DOs, ROs, and fibrils (FBs) formed in the presence of phosphatidylcholine (PC) or phosphatidylserine (PS). PC-templated DOs with predominantly parallel β-sheet structure, while PS-templated DOs were predominantly antiparallel β-sheet. These DOs were present only during the early stages of aggregation. Conversely, ROs were persistent and their structural evolution was more stochastic irrespective of the lipid environment. The secondary structure of lipid-templated DOs correlated precisely with that of early-stage FBs, highlighting their role as on-path oligomers in hIAPP aggregation. Finally, the lipid environment present during aggregation uniquely altered the structural evolution of FBs, with PC favoring a progressive increase in antiparallel β-sheet FBs and PS favoring an increase in parallel β-sheet. These results provide crucial insight into the mechanisms of hIAPP aggregation in the lipid-rich cellular environment, simultaneously solidifying lipids as critical players in the early stages of hIAPP aggregation.
    Keywords:  AFM‐IR; fibrils; hIAPP; oligomers
    DOI:  https://doi.org/10.1002/pro.70867
  4. J Pharm Pharm Sci. 2026 ;29 17216
      Alzheimer's disease (AD) is characterized by the accumulation of amyloid-β (Aβ), a pathological hallmark implicated in disease onset and progression. Aβ undergoes self-assembly from monomers into soluble oligomers, protofibrils, insoluble fibrils, and extracellular plaques. Our previous studies have shown that Jowiseungchungtang, which consists of 14 medicinal herbs, inhibits Aβ aggregation and ameliorates Aβ-mediated pathology in AD models. However, the active small molecules underlying these effects remain unidentified. To identify small molecules from these 14 medicinal herbs, we constructed a library of 1,751 compounds and applied an integrated in silico and in vitro workflow. First, these 1,751 compounds were filtered based on drug-likeness and predicted blood-brain barrier permeability, yielding 566 candidates. Second, molecular docking of 566 selected compounds against Aβ conformers identified five candidates predicted to interact with aggregation-prone residues critical for Aβ aggregation and fibril stabilization. Third, Thioflavin T assays demonstrated that four compounds-1-monopalmitin, isobutyl octyl oxalate, pentadecanoic acid, and dimethyl azelate-significantly inhibited Aβ42 aggregation. Additionally, isobutyl octyl oxalate and pentadecanoic acid disaggregated preformed Aβ42 aggregates. Fourth, molecular dynamics simulations were performed to examine the short-timescale behavior of the candidate compounds with the Aβ17-42 dimer, showing transient ligand-Aβ interactions associated with structural rearrangements at the dimer interface. Pharmacokinetic predictions supported drug-likeness, showing blood-brain barrier permeability and systemic clearance. Collectively, these findings identify four Jowiseungchungtang (JWS)-derived candidate compounds with Aβ aggregation-inhibitory activity and provide a mechanistic and pharmacokinetic basis for further development of these compounds as potential therapeutic agents in AD.
    Keywords:  Alzheimer’s disease; Aβ aggregation and dissociation; amyloid-β; computational screening; thioflavin T assay
    DOI:  https://doi.org/10.3389/jpps.2026.17216
  5. J Phys Chem B. 2026 Nov 05. 130(44): 11788-11798
      The misfolding and pathological aggregation of amyloid-β (Aβ) into insoluble amyloid deposits are closely associated with Alzheimer's disease (AD). Inhibiting early Aβ assembly is a critical strategy for the development of antiamyloid therapeutics. Hesperetin (HST), a natural flavanone abundant in citrus fruits, has been reported to inhibit Aβ fibrillogenesis and reduce Aβ-associated cytotoxicity. However, the molecular mechanism underlying HST-mediated inhibition of Aβ aggregation remains unclear. In particular, whether HST acts through mechanisms similar to other natural compounds or employs a distinct inhibitory strategy is yet to be determined. Here, we employed replica exchange molecular dynamics (REMD) simulations to investigate how HST modulates Aβ early aggregation and β-sheet assembly at the atomic level. The results demonstrate that HST disrupts the continuity of β-sheet structures within Aβ dimers, as evidenced by restricted β-strand extension. Mechanistically, HST preferentially interacts with aggregation-prone regions of Aβ through a synergistic interaction network of hydrogen-bonding, hydrophobic, π-π stacking, and cation-π interactions. Notably, HST-mediated hydrogen bonding with the Aβ backbone perturbs the local hydrogen-bonding environment required for β-sheet extension, while cooperative nonpolar and aromatic interactions further stabilize HST-bound conformations and weaken intra- and intermolecular interaction networks involved in Aβ self-assembly. Collectively, these findings reveal a specific mechanism by which HST regulates Aβ aggregation through disruption of β-sheet continuity, which provides atomic-level insights into the antiamyloid activity of natural flavanones.
    DOI:  https://doi.org/10.1021/acs.jpcb.6c06062
  6. Chembiochem. 2026 Nov 12. pii: e70583. [Epub ahead of print]27(21):
      Seven million people in the USA are estimated to suffer from Alzheimer's disease (AD), a number expected to double by 2050. Patient care costs >$350 billion/year now but will exceed $1 trillion by 2050, bankrupting our economy. Tremendous progress in understanding and treating AD has been made over the past 4 decades, yet, after >400 clinical trials, no efficacious AD treatments exist. The amyloid cascade hypothesis (ACH), the leading disease model, holds that amyloid β (Aβ) initiates a cascade leading to disease. Alternative processing cleaves APP in the middle of Aβ, producing the C-terminal fragment, p3. Simply put, if the ACH is true, no Aβ means no disease because p3 is believed soluble, non-amyloidogenic, and nontoxic. However, recent studies have shown this to be untrue. In fact, p3 is more amyloidogenic than Aβ, and is neurotoxic. It also forms mixed aggregates with Aβ that have distinct structures and neurotoxicities. ACH has led the AD field to largely ignore these facts. Here, we provide an integrated perspective on how this has come about and urge expansion of the ACH to consider the possible roles of p3 in AD and to refer to it as Amyloid α (Aα), to better reflect its nature.
    Keywords:  amyloid; amyloid cascade hypothesis; amyloid precursor protein; clinical trial; disease; medicine; neuroscience; pathogenesis
    DOI:  https://doi.org/10.1002/cbic.70583
  7. ChemMedChem. 2026 Nov 12. pii: e70558. [Epub ahead of print]21(21):
      Detecting and distinguishing between structurally diverse protein aggregates involved in various neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD), remain key challenges in the development of molecular imaging tools. Recently, bi-thiophene-vinyl-benzothiazoliums (bTVBTs), a class of thiophene-based optical ligands, were synthesized and shown to enable selective labeling of tau pathology in AD brain tissue. Building on this framework, we report here the design and evaluation of a novel series of bTVBT ligands functionalized with L-amino acids (glycine, alanine, valine, tyrosine, or glutamate) to explore their influence on ligand-filament interactions. When applied to sporadic AD brain tissue sections, the ligands displayed preferential binding to tau deposits when using 100 nM ligand, whereas all ligands bound to both amyloid-β (Aβ) and tau aggregates at higher concentrations. The glycine-functionalized bTVBT scaffold demonstrated the strongest fluorescence upon binding and was labeling all types of tau inclusions present in sAD brain tissue, whereas the glutamate-functionalized ligand was the least potent. Thus, the chemical nature of the amino acid influenced the binding mode of the ligand to protein deposits. The observed trend in the ligands' binding mode to the protein aggregates could also be correlated with distinct solvatochromic effects, indicating that certain amino acid side chains interfere with favorable interligand π-π stacking, thereby reducing binding specificity. Collectively, these results pinpoint that minor chemical alterations of the bTVBT scaffold influence the binding mode of the ligands to protein deposits, and we foresee that our findings will aid in designing ligands targeting proteinaceous aggregated species in AD and related neurodegenerative diseases.
    Keywords:  Alzheimer´s disease; amyloid β; fluorescence; ligands; tau
    DOI:  https://doi.org/10.1002/cmdc.70558
  8. Biochem Soc Trans. 2026 Nov 25. 54(11): 1581-1594
      The abundant neuronal protein α-synuclein is a key driver of Parkinson's and related diseases. α-Synuclein adopts a wide variety of different conformational states, but it is often unclear which of these species is responsible for its various behaviors, complicating efforts to combat pathologic misfolding of α-synuclein. Whereas conventional approaches struggle to provide direct, high-resolution insight into these structure-activity relationships, deep mutational scanning (DMS) has recently emerged as a powerful approach to probe the structural basis of protein activity and identify the molecular determinants of pathology. In the present review, we highlight insights from recent DMS studies of α-synuclein, which have implicated membrane binding as an important contribution to its toxicity and aggregation. Further, experiments in different cell types reveal distinct determinants of aggregation, highlighting the role of the cellular environment in shaping the conformational landscape of α-synuclein. We therefore expect that DMS will fill an important gap in the characterization of protein structure-activity relationships, particularly for conformationally dynamic proteins, including those implicated in misfolding diseases.
    Keywords:  alpha synuclein; deep mutational scanning; protein aggregation; protein misfolding
    DOI:  https://doi.org/10.1042/BST20250295
  9. bioRxiv. 2026 Oct 30. pii: 2026.10.29.762820. [Epub ahead of print]
      Medin, a 50-residue fragment of lactadherin (MFG-E8), forms aortic medial amyloid, the most common localized amyloid in humans, and co-deposits with vascular amyloid-β (Aβ) in Alzheimer's disease. In the full-length medin fibril the N-terminal half forms the entire protofilament interface, yet the strongest predicted amyloidogenic determinants lie in the C-terminal region. Here we show that this region aggregates on its own. The isolated C-terminal aggregation-prone region (medin C-APR, medin 31-53) begins to aggregate with the same lag time as full-length medin and assembles into two coexisting polymorphs, determined here by cryo-EM at 2.71 and 2.91 Å. Both are built from the same two-stranded β-arch and a pseudo-2 1 protofilament pair closed by an aromatic-aliphatic zipper, and differ only in how many accessory chains the exposed hydrophobic face recruits. The medin C-terminus therefore carries an amyloid core of its own, unrelated to that of the full-length fibril: medin has more than one aggregation-prone region, and the structural contribution of each region depends on sequence and assembly context.
    DOI:  https://doi.org/10.64898/2026.10.29.762820